Retrospective, cohort study evaluating empiric dose-reduced nab-paclitaxel with gemcitabine in metastatic pancreatic adenocarcinoma: A single institution experience
| Autor: | Alex Niu, Tahir Latif, Eric W. Mueller, Mahender Yellu, Anumeha Gupta, Olugbenga Olowokure, Alicia Gesenhues, LeeAnn Geraghty, Adam Lane, Lisa Grate |
|---|---|
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 37:456-456 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2019.37.4_suppl.456 |
| Popis: | 456 Background: The phase III MPACT trial was conducted to assess OS in patients with metastatic pancreatic adenocarcinoma (mPAC) receiving nab-paclitaxel (nab-P) 125 mg/m2 + gemcitabine (G) 1000 mg/m2 on days 1, 8, and 15 every 28 days. Due to reported increased incidence of adverse events (AEs) at this dose, practice at UC Health outside the setting of a clinical trial is to empirically dose reduce (EDR) nab-P to 100 mg/m2. This study is a review of the efficacy of EDR nab-P + G in patients with mPAC compared to MPACT data. Methods: This retrospective, single-center, cohort study included patients ≥18 years of age with mPAC (by biopsy) receiving first line therapy with EDR nab-P + G from January 1, 2012 to March 31, 2017. Primary outcome is OS. Secondary outcomes include PFS, CA19-9 percent reduction, incidence of grade ≥ 3 AEs. Results: See table. Conclusions: In patients with mPAC, EDR nab-P plus G demonstrated a median OS of 10 months and PFS of 5 months. 53% of patients had a 20% CA19-9 reduction from baseline with a 1 year OS rate of 45%. The incidence of grade ≥ 3 AEs appeared to be acceptable. [Table: see text] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|